Close Menu

Roka Bioscience

The story has been corrected to state that Roka's technology is based on transcription mediated amplification methods, not PCR technology.

NEW YORK (GenomeWeb) – Foodborne pathogen molecular diagnostics firm Roka Bioscience has filed with the US Securities and Exchange Commission to go public.

Roka Bioscience said Friday that it has secured $47.5 million in Series D financing to support the commercialization of its molecular food safety testing platform.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roka Bioscience said after the close of the market on Friday that it has raised $27.5 million toward a $47.5 million Series D financing round.

The 2009 Gen-Probe spinoff has exclusive licensing rights to various Gen-Probe nucleic acid-based tests and instrumentation for use in industrial applications.

The firm was founded two years ago in order to commercialize the industrial assets of Gen-Probe and today its CEO said that it is on track to launch its first molecular assay for food safety testing later this year.

Millipore claims that its test, which incorporates transcription-mediated amplification technology developed by Gen-Probe offshoot Roka Bioscience, provides a few advantages over PCR-based Mycoplasma testing.

Gen-Probe is spinning off its industrial testing assets into a new, independently operated company. The spin off will continue Gen-Probe's collaborations with Millipore and GE Water.

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.